Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 12:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 50 matching trials from the live ClinicalTrials.gov search.
Conditions
Respiratory Syncytial Virus Infections
Interventions
RSVPreF3 OA investigational vaccine, COVID-19 mRNA vaccine
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
841 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
8
States / cities
Coral Gables, Florida • Savannah, Georgia • Evansville, Indiana + 5 more
Conditions
COVID-19
Interventions
Flu Seasonal /SARS-CoV-2 mRNA Dose 1, Flu Seasonal /SARS-CoV-2 mRNA Dose 2, Flu Seasonal mRNA, SARS-CoV-2 mRNA Dose 1, SARS-CoV-2 mRNA Dose 2, Licensed Flu Seasonal, Licensed COVID-19 mRNA, Placebo
Combination Product · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 64 Years
Enrollment
106 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
9
States / cities
Anniston, Alabama • Rolling Hills Estates, California • Hialeah, Florida + 5 more
Conditions
Pneumococcal Infection
Interventions
V110, V114, mRNA-1273, Placebo for V110, Placebo for V114
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
50 Years and older
Enrollment
850 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
42
States / cities
North Hollywood, California • Northridge, California • Paramount, California + 38 more
Conditions
COVID-19
Interventions
SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 1, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 2, SARS-CoV-2 recombinant protein vaccine Phase 2 Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage A, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (D614)-AS03, Dosage B, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 1, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 2, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 3, SARS-CoV-2 adjuvanted recombinant protein vaccine, monovalent (B.1.351)-AS03 Alternative Exploratory Formulation 4, SARS-CoV-2 adjuvanted recombinant protein vaccine, bivalent (D614+B.1.351)-AS03
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
3,159 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
30
States / cities
Birmingham, Alabama • Chandler, Arizona • Glendale, Arizona + 26 more
Conditions
COVID-19 Pneumonia, COVID-19
Interventions
Pfizer COVID-19 mRNA vaccine, Moderna COVID-19 mRNA vaccine
Biological
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Timeline
2023
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Influenza, COVID-19
Interventions
Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster), Sequential Vaccination (Influenza vaccine then mRNA COVID booster), Sequential Vaccination (mRNA COVID booster then Influenza vaccine)
Biological
Lead sponsor
Duke University
Other
Eligibility
6 Years to 64 Years
Enrollment
455 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
8
States / cities
Phoenix, Arizona • Tempe, Arizona • Atlanta, Georgia + 4 more
Conditions
Myocardial Injury, COVID-19, Vaccine Reaction
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Conditions
Multiple Sclerosis
Interventions
SARS-COV-2 mRNA Vaccine
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Denver, Colorado • New York, New York
Conditions
COVID-19, Immunosuppression, Vaccine Response Impaired
Interventions
Reduction in antimetabolite immunosuppression
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Sacramento, California
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
65 Years and older
Enrollment
306 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
6
States / cities
Glendale, Arizona • San Diego, California • Vista, California + 3 more
Conditions
COVID-19, SARS-CoV-2 Infection
Interventions
AZD9838, Licensed SARS-CoV-2 mRNA vaccine, AZD6563
Biological
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
243 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2025
U.S. locations
5
States / cities
Long Beach, California • Rolling Hills Estates, California • Chicago, Illinois + 2 more
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

NCT04798027
Conditions
COVID-19
Interventions
SARS-CoV-2 mRNA vaccine formulation 1, SARS-CoV-2 mRNA vaccine formulation 2, SARS-CoV-2 mRNA vaccine formulation 3, Placebo (0.9% normal saline)
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
12
States / cities
Rolling Hills Estates, California • Hollywood, Florida • Miami, Florida + 9 more
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Simultaneous mRNA COVID-19 and IIV4 Vaccination Study

NCT05028361
Conditions
Quality of Life, Injection Site Reaction, Adverse Drug Event, Systemic Reaction
Interventions
mRNA COVID-19, IIV4, Placebo (saline)
Biological · Other
Lead sponsor
Duke University
Other
Eligibility
5 Years and older
Enrollment
348 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
3
States / cities
Baltimore, Maryland • Durham, North Carolina • Cincinnati, Ohio
Completed No phase listed Observational Accepts healthy volunteers

Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran

NCT06130345
Conditions
SARS-CoV-2
Interventions
SPIKEVAX
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
Not listed
Enrollment
15,196,685 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New York, New York
Conditions
COVID-19, SARS-CoV-2
Interventions
CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg), CV0501 (25 μg), CV0501 (50 μg), CV0501 (100 μg), CV0501 (200 μg)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
185 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
11
States / cities
Sacramento, California • Hollywood, Florida • Melbourne, Florida + 8 more
Conditions
SARS-CoV-2, COVID-19, Post-Acute COVID-19 Syndrome
Interventions
Pfizer-BioNTech COVID-19 mRNA vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
6 Months and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
New York, New York
Not yet recruiting Phase 2 Interventional Accepts healthy volunteers

mRNA Covid-19 Vaccine Immune Response Comparisons Using Different Delivery Routes

NCT06919796
Conditions
Evaluate Immune Responses Following mRNA COVID-19 Vaccine Administration Through Different Delivery Routes in Healthy Volunteers, SARS CoV-2
Interventions
COMIRNATY®
Biological
Lead sponsor
PharmaJet, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Decatur, Georgia
Conditions
Influenza, Human, COVID-19
Interventions
Comirnaty, Quadrivalent Influenza Vaccine
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
3,442,996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
New York, New York
Conditions
Myocarditis
Interventions
Not listed
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
Not listed
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Exercise and COVID-19 Viral T-cell Immunity

NCT05019456
Conditions
COVID-19 Respiratory Infection, Influenza
Interventions
COVID-19 Vaccine
Biological
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 44 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Tucson, Arizona
Conditions
Covid19
Interventions
SARS-CoV-2 mRNA vaccine
Biological
Lead sponsor
TruDiagnostic
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lexington, Kentucky
Conditions
SARS-CoV-2 Infection
Interventions
PRIME-2-CoV_Beta
Drug
Lead sponsor
Speransa Therapeutics
Industry
Eligibility
18 Years to 85 Years
Enrollment
103 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
5
States / cities
Florida City, Florida • Chicago, Illinois • Kansas City, Missouri + 2 more
Recruiting No phase listed Observational Accepts healthy volunteers

The Impact of COVID-19 on Maternal and Neonatal Outcomes

NCT05197621
Conditions
COVID-19, Pregnancy; Infection
Interventions
mRNA COVID-19 vaccine (Pfizer or Moderna)
Biological
Lead sponsor
Johns Hopkins University
Other
Eligibility
14 Years to 55 Years · Female only
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Conditions
COVID-19
Interventions
COVID-19 mRNA vaccine, VYD2311, Placebo (Normal Saline)
Drug
Lead sponsor
Invivyd, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
210 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Overland Park, Kansas